| [1] |
ZHONG H, ZHAO M, WU C, et al. Development of oxoisoaporphine derivatives with topoisomerase Ⅰ inhibition and reversal of multidrug resistance in breast cancer MCF-7/ADR cells[J]. Eur J Med Chem, 2022, 235:114300. doi:10.1016/j.ejmech.2022.114300URL |
| [2] |
LI Y, SUN Y, TANG T, et al. Paris saponin Ⅶ reverses chemoresistance in breast MCF-7/ADR cells[J]. J Ethnopharmacol, 2019, 232:47-54. doi:10.1016/j.jep.2018.12.018URL |
| [3] |
ZHOU B G, WEI C S, ZHANG S, et al. Matrine reversed multidrug resistance of breast cancer MCF-7/ADR cells through PI3K/AKT signaling pathway[J]. J Cell Biochem, 2018, 119(5):3885-3891. doi:10.1002/jcb.v119.5URL |
| [4] |
ZHANG Z, XU S, WANG Y, et al. Near-infrared triggered co-delivery of doxorubicin and quercetin by using gold nanocages with tetradecanol to maximize anti-tumor effects on MCF-7/ADR cells[J]. J Colloid Interface Sci, 2018, 509:47-57. doi:10.1016/j.jcis.2017.08.097URL |
| [5] |
BOYAGES J. Radiation therapy and early breast cancer: current controversies[J]. Med J Aust, 2017, 207(5):216-222. doi:10.5694/mja2.2017.207.issue-5URL |
| [6] |
YIN Y, WANG X, LI T, et al. MicroRNA-221 promotes breast cancer resistance to adriamycinviamodulation of PTEN/Akt/mTOR signaling[J]. Cancer Med, 2020, 9(4):1544-1552. doi:10.1002/cam4.v9.4URL |
| [7] |
LI Z, QIAN J, LI J, et al. Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicinviathe PI3K/AKT/mTOR signaling pathway[J]. Exp Ther Med, 2019, 18(1):435-442. |
| [8] |
SHET T. Ki-67 in breast cancer: simulacra and simulation[J]. Indian J Cancer, 2020, 57(3):231-233. |
| [9] |
HU G, ZHAO X, WANG J, et al. miR-125b regulates the drug-resistance of breast cancer cells to doxorubicin by targeting HAX-1[J]. Oncol Lett, 2018, 15(2):1621-1629. |
| [10] |
MAASHI M S, AL-MUALM M, AL-AWSI G R L, et al. Apigenin alleviates resistance to doxorubicin in breast cancer cells by acting on the JAK/STAT signaling pathway[J]. Mol Biol Rep, 2022, 49(9):8777-8784. doi:10.1007/s11033-022-07727-0 |
| [11] |
董伟, 黄小英, 谢冰斌, 等. 氧化前胡素对乳腺癌MCF-7/DOX细胞多柔比星耐药的抑制作用[J]. 中国临床药理学与治疗学, 2022, 27(3):260-266. |
|
DONG W, HUANG X Y, XIE B B, et al. Effects of oxy-peucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin[J]. Chin J Clin Pharmacol Ther, 2022, 27(3):260-266. |
| [12] |
张如月, 李朵璐, 杨哲, 等. 外泌体介导乳腺癌MCF-7细胞对多柔比星耐药性的机制[J]. 药学学报, 2019, 54(5):861-866. |
|
ZHANG R Y, LI D L, YANG Z, et al. Mechanisms of doxorubicin resistance of breast cancer MCF-7 cells mediated by exosomes[J]. Acta Pharm Sin, 2019, 54(5):861-866. |
| [13] |
杨清, 杨海松, 张世泳, 等. miRNA-27a在人乳腺癌MCF-7/ADR细胞株中的表达及其对细胞耐药的影响[J]. 实用肿瘤杂志, 2021, 36(1):28-32. |
|
YANG Q, YANG H S, ZHANG S Y, et al. Expression of miRNA-27a in human breast cancer MCF-7/ADR cell line and its effect on cell resistance[J]. J Pract Oncol, 2021, 36(1):28-32. |
| [14] |
任潇毅, 吉文仲. 多西紫杉醇联合表阿霉素序贯化疗对早期乳腺癌病人Ki-67表达及心肌功能的影响[J]. 实用癌症杂志, 2020, 35(9):1415-1418,1422. |
|
REN X Y, JI W Z. Effect on Ki-67 expression and myocardiai function in patients with early breast cancer by using docetaxel combined with epirubicin sequential chemotherapy[J]. Pract J Cancer, 2020, 35(9):1415-1418,1422. |